(HealthDay News) — Twenty-three percent of adolescents and young adults (AYAs) with sarcoma who were previously opioid-naive and used opioids during treatment had new persistent opioid use after treatment, according to a study published online May 23 in Cancer.
Melissa P. Beauchemin, Ph.D., from the Columbia University Irving Medical Center in New York City, and colleagues describe patterns of new persistent opioid use among AYAs in the year after sarcoma treatment.
Data were included for 938 opioid-naive patients aged 10 to 26 years who were diagnosed with sarcoma from 2008 to 2016. The primary outcome was new persistent opioid use, defined as two or more opioid prescriptions in the 12 months following completion of treatment.
The researchers found that 64 percent of patients filled an opioid prescription during treatment. Of these, 77 and 23 percent received no further prescriptions after the completion of therapy and received at least two prescriptions in the year following treatment, respectively.
The likelihood of new persistent use was increased in association with Medicaid versus commercial insurance (odds ratio, 1.74) and non-soft tissue sarcoma (odds ratios, 3.23 and 2.05 for Ewing sarcoma and osteosarcoma, respectively).
“Because high-quality pain management is a critical component of cancer care and AYAs are a vulnerable population at risk for opioid misuse and overdose, there is an urgent need to develop AYA-specific pain management guidelines, education, and anticipatory guidance,” the authors write.
One author disclosed financial ties to Merck.